Entering text into the input field will update the search result below

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position

Dec. 04, 2021 1:00 AM ETKaryopharm Therapeutics Inc. (KPTI)21 Comments


  • Karyopharm Therapeutics reported their Q3 earnings with a beat on revenue and a slight miss on EPS. The company revealed that XPOVIO is making inroads into multiple myeloma.
  • Despite the encouraging earnings, the ticker has been sucked into the small-cap sell-off. I am looking to take advantage of the discounted share price and reload my KPTI position.
  • I will review the company's Q3 earnings and will also highlight points that help bolster investor sentiment. In addition, I reveal my plans for accumulating KPTI as we leave 2021.

Cancer cells vis

koto_feja/E+ via Getty Images

Karyopharm Therapeutics (NASDAQ:KPTI) continues to advance their pipeline and execute on the market. The company beat the Street's earnings estimates despite strong COVID-19 headwinds. Sadly, the share price has been sucked into the small-cap sell-off

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of KPTI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.